当前位置: X-MOL 学术Colorectal Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome
Colorectal Disease ( IF 2.9 ) Pub Date : 2021-09-02 , DOI: 10.1111/codi.15899
Nigel P Murray 1, 2 , Ricardo Villalon 3 , Dan Hartmann 2 , Maria Patricia Rodriguez 1 , Socrates Aedo 2
Affiliation  

Minimal residual disease (MRD) is the net result of the biological properties of disseminated tumour cells and the effect of the immune system and treatment to eliminate them. The aim of this work is to report the changes in MRD status and immune function (lymphocyte count) after FOLFOX chemotherapy, and the outcome in Stage III colon cancer patients.

中文翻译:

III 期结肠癌 FOLFOX 化疗后免疫功能障碍的改善与微小残留病预后亚型和结果的改善相关

微小残留病(MRD)是播散性肿瘤细胞的生物学特性以及免疫系统和消除它们的治疗作用的最终结果。这项工作的目的是报告 FOLFOX 化疗后 MRD 状态和免疫功能(淋巴细胞计数)的变化,以及 III 期结肠癌患者的结果。
更新日期:2021-09-02
down
wechat
bug